NL8300444A - Intermediair materiaal voor iontoforese en contactoplossing voor de behandeling van chronische pijnsyndromen. - Google Patents
Intermediair materiaal voor iontoforese en contactoplossing voor de behandeling van chronische pijnsyndromen. Download PDFInfo
- Publication number
- NL8300444A NL8300444A NL8300444A NL8300444A NL8300444A NL 8300444 A NL8300444 A NL 8300444A NL 8300444 A NL8300444 A NL 8300444A NL 8300444 A NL8300444 A NL 8300444A NL 8300444 A NL8300444 A NL 8300444A
- Authority
- NL
- Netherlands
- Prior art keywords
- iontophoresis
- formula
- compound
- vinblastine
- microtubule inhibitor
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 34
- 239000000463 material Substances 0.000 title claims description 28
- 208000002193 Pain Diseases 0.000 title claims description 20
- 208000011580 syndromic disease Diseases 0.000 title claims description 7
- 208000000094 Chronic Pain Diseases 0.000 title 1
- 239000000243 solution Substances 0.000 claims description 27
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 20
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 20
- 230000036407 pain Effects 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 229940122255 Microtubule inhibitor Drugs 0.000 claims description 13
- 229960003048 vinblastine Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229960004528 vincristine Drugs 0.000 claims description 7
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 7
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- GLDSBTCHEGZWCV-HLTPFJCJSA-N leuroformine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C=O)=C2C=C1OC GLDSBTCHEGZWCV-HLTPFJCJSA-N 0.000 claims description 5
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 229960004355 vindesine Drugs 0.000 claims description 4
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- OBMKRZCOTHZPOB-NZSNZZHBSA-N methyl (1R,9R,10R,12R,19S)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate Chemical compound CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@@](CC)(C[C@]1(O)C(=O)OC)[C@@H]23 OBMKRZCOTHZPOB-NZSNZZHBSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 2
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 2
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- -1 1eurosine Chemical compound 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960002773 hyaluronidase Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 25
- 239000013543 active substance Substances 0.000 description 16
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 12
- 229960004982 vinblastine sulfate Drugs 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 208000022371 chronic pain syndrome Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU82384A HU185691B (en) | 1982-02-09 | 1982-02-09 | Process for preparing a new analgetic pharmaceutical composition |
| HU38482 | 1982-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8300444A true NL8300444A (nl) | 1983-09-01 |
Family
ID=10949360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8300444A NL8300444A (nl) | 1982-02-09 | 1983-02-05 | Intermediair materiaal voor iontoforese en contactoplossing voor de behandeling van chronische pijnsyndromen. |
Country Status (9)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU185691B (en) * | 1982-02-09 | 1985-03-28 | Richter Gedeon Vegyeszet | Process for preparing a new analgetic pharmaceutical composition |
| US5135477A (en) * | 1984-10-29 | 1992-08-04 | Medtronic, Inc. | Iontophoretic drug delivery |
| US4915685A (en) * | 1986-03-19 | 1990-04-10 | Petelenz Tomasz J | Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange |
| US4886489A (en) * | 1986-03-19 | 1989-12-12 | Jacobsen Stephen C | Flow-through methods and apparatus for iontophoresis application of medicaments at a controlled pH |
| US4752285B1 (en) * | 1986-03-19 | 1995-08-22 | Univ Utah Res Found | Methods and apparatus for iontophoresis application of medicaments |
| US4731049A (en) * | 1987-01-30 | 1988-03-15 | Ionics, Incorporated | Cell for electrically controlled transdermal drug delivery |
| WO1989006989A1 (en) * | 1988-01-29 | 1989-08-10 | The Regents Of The University Of California | Iontophoretic non-invasive sampling or delivery device |
| US5362307A (en) * | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
| US5023085A (en) * | 1989-11-29 | 1991-06-11 | Pfizer Inc. | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals |
| US5084008A (en) * | 1989-12-22 | 1992-01-28 | Medtronic, Inc. | Iontophoresis electrode |
| US6004309A (en) | 1990-03-30 | 1999-12-21 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
| US5125894A (en) * | 1990-03-30 | 1992-06-30 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
| US5087241A (en) * | 1990-07-24 | 1992-02-11 | Empi, Inc. | Iontophoresis electrode with reservoir and injection site |
| USRE39300E1 (en) | 1993-01-28 | 2006-09-19 | Virginia Commonwealth University Medical College Of Virginia | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
| US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| US5885241A (en) | 1997-05-29 | 1999-03-23 | Orton; Kevin R. | Treatment with an electrically-activated substance |
| US6920884B2 (en) * | 1997-05-29 | 2005-07-26 | Kevin Orton | Method of providing cosmetic/medical therapy |
| UA78672C2 (en) | 1999-04-09 | 2007-04-25 | Kevin R Orton | Method for preparation and use of conductive medicinal substance (variants) |
| US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| JP5592790B2 (ja) * | 2007-08-06 | 2014-09-17 | トリニティ ラボラトリーズ インコーポレイテッド | 慢性疼痛およびニューロパシーに関連する疼痛を治療する医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE603705C (de) * | 1931-06-18 | 1934-10-08 | Desider Deutsch Dr | Elektrode zur Einfuehrung von Heilmitteln in den Koerper mittels Iontophorese |
| US3163166A (en) * | 1961-04-28 | 1964-12-29 | Colgate Palmolive Co | Iontophoresis apparatus |
| US3734097A (en) * | 1969-04-01 | 1973-05-22 | Alza Corp | Therapeutic adhesive tape |
| US3677268A (en) * | 1969-11-28 | 1972-07-18 | Sherwood Medical Ind Inc | Iontophoresis electrode |
| US3749784A (en) * | 1972-05-03 | 1973-07-31 | Lilly Co Eli | Psoriasis treatment |
| US4029663A (en) * | 1975-07-10 | 1977-06-14 | Eli Lilly And Company | Dimeric anhydro-vinca derivatives |
| US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
| US4115388A (en) * | 1977-03-30 | 1978-09-19 | Eli Lilly And Company | 3'-Oxygenated derivatives of 4'-deoxy VLB "A" and "B" and related 1-formyl compounds |
| HU180924B (en) * | 1977-05-20 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing leurosine-type alkaloides |
| GB2089806B (en) * | 1977-11-07 | 1982-11-24 | Lilly Co Eli | 4-desacetoxy-oxo-indole-dyhydroindole intermediates |
| HU185691B (en) * | 1982-02-09 | 1985-03-28 | Richter Gedeon Vegyeszet | Process for preparing a new analgetic pharmaceutical composition |
-
1982
- 1982-02-09 HU HU82384A patent/HU185691B/hu not_active IP Right Cessation
-
1983
- 1983-02-05 NL NL8300444A patent/NL8300444A/nl not_active Application Discontinuation
- 1983-02-07 FR FR8301852A patent/FR2521007B1/fr not_active Expired
- 1983-02-07 CH CH686/83A patent/CH660968A5/de not_active IP Right Cessation
- 1983-02-07 US US06/464,573 patent/US4602909A/en not_active Expired - Fee Related
- 1983-02-08 DE DE19833304246 patent/DE3304246A1/de active Granted
- 1983-02-08 GB GB08303382A patent/GB2116037B/en not_active Expired
- 1983-02-08 BE BE0/210075A patent/BE895850A/fr not_active IP Right Cessation
- 1983-02-09 JP JP58018966A patent/JPS58198420A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB8303382D0 (en) | 1983-03-16 |
| HU185691B (en) | 1985-03-28 |
| CH660968A5 (de) | 1987-06-30 |
| JPS58198420A (ja) | 1983-11-18 |
| GB2116037B (en) | 1985-10-09 |
| JPH0414081B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-03-11 |
| FR2521007A1 (fr) | 1983-08-12 |
| GB2116037A (en) | 1983-09-21 |
| DE3304246A1 (de) | 1983-08-18 |
| US4602909A (en) | 1986-07-29 |
| BE895850A (fr) | 1983-08-08 |
| DE3304246C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-03-07 |
| FR2521007B1 (fr) | 1986-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8300444A (nl) | Intermediair materiaal voor iontoforese en contactoplossing voor de behandeling van chronische pijnsyndromen. | |
| US5334138A (en) | Method and composition for increased skin concentration of active agents by iontophoresis | |
| Lundblad et al. | Increased vascular permeability in rat nasal mucosa induced by substance P and stimulation of capsaicin-sensitive trigeminal neurons | |
| Costello et al. | Iontophoresis: applications in transdermal medication delivery | |
| EP2285362B1 (en) | Composition for transdermal delivery of cationic active agents | |
| CA1330295C (en) | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas | |
| JP2002524409A (ja) | 徐方性ドラッグデリバリー | |
| KR20080058432A (ko) | 활성 약제의 전신 전달을 위한 이온삼투 방법 및 장치 | |
| MX2007006190A (es) | Metodo de suministro de iones metalicos terapeuticos, aleaciones y sales. | |
| US20030144625A1 (en) | Method and apparatus for the treatment of infections of the nail matrix and nail plate | |
| CN101316623A (zh) | 系统输送活性剂的离子电渗方法和装置 | |
| AT413489B (de) | Elektrotransporteinrichtung zur verabreichung eines als fentanylsalz oder als sufentanilsalz vorliegenden analgetischen medikaments | |
| DE60018704T2 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| EP0448299B1 (en) | Composition for increased skin concentration of active agents by iontophoresis | |
| KR101959524B1 (ko) | 리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템 | |
| Schoenfisch et al. | Covalent surface chemical modification of electrodes for cardiac pacing applications | |
| DE69716676T2 (de) | Mittel zur Arzneistoffverabreichung durch Iontophorese | |
| WO2011013359A1 (ja) | イオントフォレーシス用薬剤組成物 | |
| DE69324476T2 (de) | Neue Morphinzusammensetzungen für iontophoretische Verabreichung | |
| Ansari et al. | Iontophoretic drug delivery systems | |
| US20050059574A1 (en) | Compositions of stable T3 and methodes of use thereof | |
| KR100315160B1 (ko) | 피부수렴제가첨가된경피투여용약제조성물 | |
| Thuesen et al. | Lower chronic stimulation threshold in the carbon‐tip than in the platinum‐tip endocardial electrode: A randomized study | |
| EP1351673B1 (en) | Compositions of stable t3 and use thereof | |
| Costello | The optimization of drug delivery with iontophoresis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1A | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| A85 | Still pending on 85-01-01 | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |